

hVIVO plc
("hVIVO" or the "Company")

Result of AGM

hVIVO plc (AIM & Euronext: HVQ) (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that all resolutions put to shareholders at the Company's Annual General Meeting held earlier today were duly passed.

For further information please contact:

hVIVO plc Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer	+44 (0) 20 7756 1300
Liberum Capital (Nominated Adviser and Joint Broker) Ben Cryer, Edward Mansfield, Phil Walker, Will King	+44 (0) 20 3100 2000
finnCap plc (Joint Broker) Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)	+44 (0) 20 7220 0500
Davy (Euronext Growth Adviser and Joint Broker) Anthony Farrell, Niall Gilchrist	+353 (0) 1 679 6363
Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson	+44 (0) 20 7933 8780 or hvivo@walbrookpr.com +44 (0) 7796 794 663 / +44 (0) 7867 984 082 / +44 (0) 7747 515 393

Notes to Editors

About hVIVO

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Company has world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capability via its [FluCamp](#) volunteer screening facilities in London and Manchester.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGSEDFEDESEDI